Related Experiment Video
Updated: Apr 15, 2026

Dynamic Visual Tests to Identify and Quantify Visual Damage and Repair Following Demyelination in Optic Neuritis Patients
Published on: April 14, 2014
Challenges and opportunities in designing clinical trials for neuromyelitis optica
Brian G Weinshenker1, Gerard Barron1, Jacinta M Behne1
1From the Department of Neurology (B.G.W.), Mayo Clinic, Rochester, MN; MedImmune Ltd. (G.B., A.F.), Riverside Building, Granta Park, Great Abington, Cambridge, UK; Guthy-Jackson Foundation (J.M.B., K.V.H.), San Diego, CA; Departments of Neurology and Ophthalmology (J.L.B.), University of Colorado Denver, Aurora; Novartis Pharmaceuticals Corporation (P.S.C.), East Hanover, NJ; Department of Neurology (B.A.C.C.), University of California San Francisco; CIC (Clinical Investigation Center) INSERM and UMR 1119 (J.d.S.), INSERM, Federation de Medecine Translationelle de Strasbourg, Université de Strasbourg; Department of Multiple Sclerosis Therapeutics (K.F.), Tohoku University, Sendai, Japan; Department of Neurology (B.G.), University of Texas Southwestern; Chugai Pharma USA (S.H., A.T.M.), Berkeley Heights, NJ; PPD Inc. (W.H.), Wilmington, NC; Department of Neurology (O.K.), Wayne State University, Detroit, MI; Teva Pharmaceuticals (V.K.), Frazer, PA; Department of Neurology (V.K.), Heinrich-Heine University, Dusseldorf, Germany; Department of Neurology (M.L.), Johns Hopkins University, Baltimore, MD; Department of Neurology (J.P.), Oxford University Hospital Trust, UK; Department of Ophthalmology and Visual Sciences (T.J.S.), Kellogg Eye Center, and Division of Metabolism, Endocrine, and Diabetes, Department of Internal Medicine, University of Michigan Medical School, Ann Arbor; Department of Health Science (M.P.S.), University of Genoa, Italy; David Geffen School of Medicine at UCLA (K.V.H.), Los Angeles, CA; GlaxoSmithKline (S.V.), Research Triangle Park, NC; Center of Neuroimmunology (P.V.), Institute of Biomedical Research August Pi Sunyer (IDIBAPS)-Hospital Clinic Barcelona, Villarroel, Spain; United States Food and Drug Administration (M.K.W.), Center for Drug Evaluation and Research, Silver Spring, MD; Alexion Pharmaceuticals Inc. (W.W.), Cheshire, CT; Department of Neurology (D.M.W.), Mayo Clinic, Scottsdale, AZ; Department of Medicine (M.R.Y.), Divisions of M
Abstract:
Current management of neuromyelitis optica (NMO) is noncurative and only partially effective. Immunosuppressive or immunomodulatory agents are the mainstays of maintenance treatment. Safer, better-tolerated, and proven effective treatments are needed. The perceived rarity of NMO has impeded clinical trials for this disease. However, a diagnostic biomarker and recognition of a wider spectrum of NMO presentations has expanded the patient population from which study candidates might be recruited. Emerging insights into the pathogenesis of NMO have provided rationale for exploring new therapeutic targets. Academic, pharmaceutical, and regulatory communities are increasingly interested in meeting the unmet needs of patients with NMO. Clinical trials powered to yield unambiguous outcomes and designed to facilitate rapid evaluation of an expanding pipeline of experimental agents are needed. NMO-related disability occurs incrementally as a result of attacks; thus, limiting attack frequency and severity are critical treatment goals. Yet, the severity of NMO and perception that currently available agents are effective pose challenges to study design. We propose strategies for NMO clinical trials to evaluate agents targeting recovery from acute attacks and prevention of relapses, the 2 primary goals of NMO treatment. Aligning the interests of all stakeholders is an essential step to this end.
More Related Videos
09:29Induction of Paralysis and Visual System Injury in Mice by T Cells Specific for Neuromyelitis Optica Autoantigen Aquaporin-4
Published on: August 21, 2017
05:44Author Spotlight: Creating a Versatile Experimental Autoimmune Encephalomyelitis Model Relevant for Both Male and Female Mice
Published on: October 13, 2023
Related Concept Videos
Clinical Trials: Overview
Clinical Trials
There are four phases in a clinical trial. A phase one...
Myasthenia Gravis: Overview and Treatment
These antibodies interfere with the function of the nicotinic receptors in three ways: by binding to the receptor and disrupting acetylcholine binding; by causing cross-linking of receptors which...